Literature DB >> 11304731

Androgen receptor expression in androgen-independent prostate cancer cell lines.

A Chlenski1, K Nakashiro , K V Ketels, G I Korovaitseva, R Oyasu.   

Abstract

BACKGROUND: Almost all attempts at establishing prostate carcinoma cell lines have resulted in generation of cells that are androgen-independent, including commonly used LNCaP which expresses androgen receptor (AR) and AR-negative Du145 and PC-3. We attempted to clarify the mechanism(s) responsible for the failure to respond to androgen.
METHODS: Cell lines LNCaP, CWR22R, PC-3, Du145, and CA7T2CL were used to examine the AR promoter function with a reporter gene assay and its methylation status by Southern blot, PCR of bisulfite-converted DNA, and 5-aza-2'-deoxycytidine treatment. Structural abnormalities of the AR were identified by sequencing of reverse-transcribed mRNA.
RESULTS: All tested AR-positive prostate carcinoma cells were capable of AR transcription at a significantly higher level than PC-3 and Du145, thus suggesting relative deficiency of the transcription factors in the AR-negative cells, further associated with methylation. Examination of CWR22R cells, which express the AR but are androgen-independent, identified an in-frame duplication of exon 3, which resulted in insertion of 39 amino acids in the DNA-binding domain.
CONCLUSIONS: Relative deficiency of transcription factors associated with methylation is responsible for the lack of AR promoter function in most of AR-negative cell lines. Mutations in the AR gene are present in the cells that express the AR but are androgen-independent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304731     DOI: 10.1002/pros.1048

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  45 in total

1.  Co-localization of sorting nexin 2 and androgen receptor in the song system of juvenile zebra finches.

Authors:  Di Wu; Yu Ping Tang; Juli Wade
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

2.  The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

Authors:  Corinne Beinat; Tom Haywood; Yun-Sheng Chen; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 3.  Role of desumoylation in the development of prostate cancer.

Authors:  Jinke Cheng; Tasneem Bawa; Peng Lee; Limin Gong; Edward T H Yeh
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.

Authors:  Megan A Chang; Micaela Morgado; Curtis R Warren; Cimona V Hinton; Mary C Farach-Carson; Nikki A Delk
Journal:  Prostate       Date:  2013-09-30       Impact factor: 4.104

Review 5.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

6.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

7.  ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes.

Authors:  Na Li; Yuanyuan Li; Jie Lv; Xiangdong Zheng; Hong Wen; Hongjie Shen; Guangjing Zhu; Tsai-Yu Chen; Shilpa S Dhar; Pu-Yeh Kan; Zhibin Wang; Ramin Shiekhattar; Xiaobing Shi; Fei Lan; Kaifu Chen; Wei Li; Haitao Li; Min Gyu Lee
Journal:  Mol Cell       Date:  2016-07-28       Impact factor: 17.970

8.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.

Authors:  Tanya Stoyanova; Aaron R Cooper; Justin M Drake; Xian Liu; Andrew J Armstrong; Kenneth J Pienta; Hong Zhang; Donald B Kohn; Jiaoti Huang; Owen N Witte; Andrew S Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

9.  Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management.

Authors:  Howard B Lieberman; Alex J Rai; Richard A Friedman; Kevin M Hopkins; Constantinos G Broustas
Journal:  Transl Cancer Res       Date:  2018-01-14       Impact factor: 1.241

10.  CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.

Authors:  Huiying Sun; Sanjay N Mediwala; Adam T Szafran; Michael A Mancini; Marco Marcelli
Journal:  Horm Cancer       Date:  2016-03-08       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.